• PDK4-IN-1 Hydrochloride: Precision Modulation of Mitochondri

  2026-07-03

  Explore how PDK4-IN-1 hydrochloride, a pyruvate dehydrogenase kinase 4 inhibitor, enables advanced control of mitochondrial energy metabolism and cellular signaling. This article uncovers mechanistic insights, practical assay considerations, and the translational significance of selective PDK4 inhibition beyond existing guides.

• EAGLE-1 Phase 3: Oral Gepotidacin vs. Standard Therapy for G

  2026-07-02

  The EAGLE-1 phase 3 trial demonstrated that oral gepotidacin is non-inferior to the combination of intramuscular ceftriaxone and oral azithromycin in treating uncomplicated urogenital gonorrhoea. This large, multicentre study addresses the urgent need for new oral antibiotics against Neisseria gonorrhoeae and provides robust evidence for gepotidacin as a viable future therapeutic option.

• LLY507: Advancing Selective SMYD2 Inhibition for Translation

  2026-07-02

  Explore how LLY507, a potent SMYD2 inhibitor, enables precise interrogation of cytoplasmic methylation and its impact on cancer proliferation and renal fibrosis. This article uniquely dissects SMYD2's substrate specificity and practical assay implications, offering advanced guidance for translational scientists.

• Colloid-Engineered LNP Emulsions Enable Targeted mRNA Delive

  2026-07-01

  Zhou et al. present a lipid nanoparticle-stabilized emulsion (LSE) system that enables spatiotemporal control of mRNA delivery, selectively targeting antigen-presenting cells to enhance T cell immunity. This approach addresses limitations of conventional LNPs, resulting in durable, potent cellular responses and advancing the rational design of mRNA-based vaccines and immunotherapies.

• Carbapenemase Genes and Multidrug Resistance in CREC: Insigh

  2026-07-01

  This study systematically characterizes carbapenemase-encoding genes in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong, China. Key findings include high rates of blaNDM-1 carriage, frequent multidrug resistance, and robust plasmid-mediated gene transfer, with epidemiological impacts for patient populations and clinical management.

• Kir2.1 Inhibition Reduces PASMC Proliferation in PH Models

  2026-06-30

  This study establishes Kir2.1 as a key regulator of pulmonary artery smooth muscle cell (PASMC) proliferation and migration in pulmonary hypertension (PH). Using selective inhibition, the research delineates the Kir2.1-TGF-β1/SMAD2/3 axis as a mechanistic driver of vascular remodeling, supporting new experimental approaches for cardiovascular ion channel research.

• A 83-01: Strategic ALK-5 Inhibition for Translational Scienc

  2026-06-30

  Explore the mechanistic and strategic value of A 83-01, a selective ALK-5 inhibitor, in advancing TGF-β pathway research, differentiation protocols, and next-gen translational applications. Grounded in recent evidence and competitive insights, this article delivers actionable guidance for researchers aiming to optimize cellular models, dissect EMT, and accelerate clinical impact.

• CF10 and EdU Synergy Drives Telomere Attrition in CRC Cells

  2026-06-29

  This study demonstrates that combining the fluoropyrimidine polymer CF10 with 5-ethynyl-2′-deoxyuridine (EdU) induces synergistic telomere attrition and mitotic catastrophe in colorectal cancer cells. The findings reveal a novel mechanism for enhancing telomerase-targeted therapies and inform the rational design of future combinatorial cancer treatments.

• Methicillin Resistance in Staphylococcus aureus: Clinical an

  2026-06-29

  This review synthesizes the landmark findings of Turner et al., highlighting the molecular origins and clinical consequences of methicillin resistance in Staphylococcus aureus. The paper's integration of epidemiology, genetic mechanisms, and translational challenges provides a comprehensive resource for researchers studying bacterial cell wall synthesis inhibitors and antibiotic resistance.

• Gepotidacin: Mechanism, Benchmarks, and Research Integration

  2026-06-28

  Gepotidacin (GSK2140944) is a first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV with high potency. It is effective against multidrug-resistant pathogens and supports advanced antibacterial research applications. APExBIO supplies Gepotidacin (BA1220) for laboratory use, enabling reliable mechanistic and efficacy studies.

• Propranolol: Applied Workflows in Essential Tremor and Beyon

  2026-06-27

  Propranolol, a non-selective β-adrenergic receptor blocker, enables cutting-edge research in cardiovascular, neurobehavioral, and metabolic domains. This article unpacks practical workflows, troubleshooting tips, and comparative advantages, translating novel mechanistic findings into actionable lab protocols.

• Anti-Inflammatory and Anti-Angiogenic Stents for TISR Suppre

  2026-06-26

  Zhao et al. present a dual-function airway stent that integrates anti-inflammatory and anti-angiogenic strategies to address tracheal in-stent restenosis (TISR). Their work demonstrates that targeted modulation of inflammation and vascularization can significantly reduce restenosis risk, providing a robust translational framework for airway device innovation.

• Aztreonam as a Precision Tool in Gram-Negative Antibiotic Re

  2026-06-26

  Explore how Aztreonam, a monocyclic β-lactam antibiotic, enables advanced investigations into Gram-negative bacterial resistance and host-drug interactions. This article uniquely examines Aztreonam’s experimental value for pharmacokinetic and toxicity modeling, bridging insights from recent resistance studies.

• Azithromycin (SKU B1398): Reliable Solutions for Bacterial R

  2026-06-25

  This article provides scenario-driven guidance for life science researchers using Azithromycin (SKU B1398) in cell viability, proliferation, and cytotoxicity assays. Emphasizing protocol robustness, vendor reliability, and workflow optimization, it demonstrates how Azithromycin addresses real-world laboratory challenges with data-backed specificity.

• Crystal Violet Staining: Elevating Fungal Biofilm Research

  2026-06-25

  This article explores the mechanistic and strategic value of Crystal Violet Staining Solution for translational researchers investigating fungal biofilms, drug resistance, and cellular dynamics. Drawing on recent molecular epidemiology of Candidozyma auris, it highlights best practices and emerging paradigms, while positioning APExBIO's staining solution as an enabling technology for robust, reproducible cell-based assays.

413 records 10/28 page Previous Next First page 上5页 678910 下5页 Last page